Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells
- 1 September 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (9) , 1410-1415
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Antiangiogenic Therapy for Cancer: An UpdateThe Cancer Journal, 2007
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Multi-kinase inhibitors create buzz at ASCONature Biotechnology, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002
- Angiogenesis in cancer and other diseasesNature, 2000